Ruxolitinib In the Treatment of Myelofibrosis

Yang, Lily P. H.; Keating, Gillian M.
September 2012
Drugs;2012, Vol. 72 Issue 16, p2117
Academic Journal
Ruxolitinib is a selective inhibitor of Janus kinases (JAK) 1 and 2, which are involved in the signalling pathway of various cytokines and growth factors essential to haematopoiesis. JAK 1 and 2 are implicated in the development of myelofibrosis, as well as other haematological malignancies. Ruxolitinib is the first agent approved for the treatment of myelofibrosis. In a randomized, double-blind, placebo-controlled, multicentre trial (COMFORT-I) in patients with myelofibrosis, significantly more ruxolitinib than placebo recipients achieved a >35% reduction in spleen volume (primary endpoint) at 24 weeks. In a randomized, open-label, multicentre trial (COMFORT- II) in patients with myelofibrosis, significantly more ruxolitinib than best available therapy recipients achieved the same primary endpoint at 48 weeks. Significantly more ruxolitinib than placebo recipients achieved a >50% reduction in Total Symptom Score at 24 weeks in COMFORT-I. Ruxolitinib generally improved health-related quality-of-life scores, while best available therapy was generally associated with worsened scores at 48 weeks in COMFORT-II. In COMFORT-I, overall survival data appeared to favour ruxolitinib over placebo; of note, most placebo recipients had crossed over to receive ruxolitinib. In COMFORT- II, a significant difference in overall survival between ruxolitinib and best available therapy was not shown; this trial was not powered to detect such a difference. In clinical trials in patients with myelofibrosis, ruxolitinib was generally associated with an acceptable tolerability profile. In the placebo-controlled trial, the most commonly reported grade 3 or 4 adverse events in ruxolitinib recipients were thrombocytopenia, anaemia and neutropenia. These haematological adverse events were mainly managed with dosage interruptions/reductions and/or transfusions, and rarely resulted in discontinuation.


Related Articles

  • Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Portaccio, Emilio // Core Evidence;2011, Vol. 6 Issue 1, p13 

    Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous system and represents one of the most common causes of chronic neurologic disability in young adults. All the current disease-modifying drugs are administered parenterally, and can be associated with...

  • Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab. Calzone, Frank J.; Cajulis, Elaina; Chung, Young-Ah; Tsai, Mei- Mei; Mitchell, Petia; Lu, John; Chen, Ching; Sun, Jilin; Radinsky, Robert; Kendall, Richard; Beltran, Pedro J. // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Background: Therapeutic antibodies targeting the IGF1R have shown diverse efficacy and safety signals in oncology clinical trials. The success of these agents as future human therapeutics depends on understanding the specific mechanisms by which these antibodies target IGF1R signaling. ...

  • Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Minturn, Jane; Evans, Audrey; Villablanca, Judith; Yanik, Gregory; Park, Julie; Shusterman, Suzanne; Groshen, Susan; Hellriegel, Edward; Bensen-Kennedy, Debra; Matthay, Katherine; Brodeur, Garrett; Maris, John // Cancer Chemotherapy & Pharmacology;Oct2011, Vol. 68 Issue 4, p1057 

    Purpose: TrkB acts as an oncogenic kinase in a subset of human neuroblastomas. Lestaurtinib, a multi-kinase inhibitor with potent activity against Trk kinases, has demonstrated activity in preclinical models of neuroblastoma. Methods: Patients with refractory high-risk neuroblastoma received...

  • Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer. Keating, Gillian M. // Drugs;2012, Vol. 72 Issue 3, p353 

    The humanized monoclonal antibody pertuzu-mab is the first in a new class of drugs, the human epidermal growth factor receptor (HER) dimeriza-tion inhibitors. Given that pertuzumab binds to a different epitope of the HER2 extracellular domain than trastuzumab, combination therapy with...

  • Indywidualizacja terapii przeciwnowotworowej; molekularne uwarunkowania mechanizmów dziaÅ‚ania nowoczesnych leków onkologicznych. Regulska, Katarzyna; Stanisz, Beata; Regulski, Miłosz // Advances in Hygiene & Experimental Medicine / Postepy Higieny i ;2012, Vol. 66, p855 

    Deregulation of cellular signal transduction, caused by gene mutations, has been recognized as a basic factor of cancer initiation, promotion and progression. Thus, the ability to control the activity of overstimulated signal molecules by the use of appropriate inhibitors became the idea of...

  • Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Battaggia, Alessandro; Donzelli, Alberto; Font, Maria; Molteni, Davide; Galvano, Antonio // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Background: Randomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe+simvastatin, on mortality and morbidity...

  • Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Osorio, Marta; Gracia, Elias; Reigosa, Edmundo; Hernandez, Julio; de la Torre, Ana; Saurez, Giselle; Perez, Kirenia; Viada, Carmen; Cepeda, Meylán; Carr, Adriana; Ávila, Yisel; Rodríguez, Migdalia; Fernandez, Luis E. // Cancer Management & Research;2012 Part 2, Vol. 4, p341 

    NeuGc-containing gangliosides have been described in melanoma cells and are an attractive target for cancer immunotherapy because they are minimally or not expressed in normal human tissues. Melanoma patients treated with a vaccine based on N-glycolyl gangliosides have shown benefit in...

  • MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Srivastava, Sanjeev K.; Bhardwaj, Arun; Singh, Seema; Arora, Sumit; Wang, Bin; Grizzle, William E.; Singh, Ajay P. // Carcinogenesis;Dec2011, Vol. 32 Issue 12, p1832 

    Pancreatic cancer (PC) has the worst prognosis among all cancers due to its late diagnosis and lack of effective therapies. Therefore, identification of novel gene targets, which are differentially expressed in PC and functionally involved in malignant phenotypes, is critical to achieve early...

  • Eptifibatide: The evidence for its role in the management of acute coronary syndromes. Shah, Ibrahim; Khan, Shakeel O.; Malhotra, Surender; Fischell, Tim // Core Evidence;2009, Vol. 4 Issue 1, p49 

    Introduction: Acute coronary syndromes and non-Q-wave myocardial infarction are often initiated by platelet activation. Eptifibatide is a cyclic heptapeptide and is the third inhibitor of glycoprotein (Gp) IIb/IIIa that has found broad acceptance after the specific antibody abciximab and the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics